Biotechnology Companies in the News – January 2012

Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to email their news releases to BioNJ.

January 12
Immunomedics Announces Presentations at Gastrointestinal Cancers Symposium Showcasing Advances in Pancreatic Cancer Diagnosis and Therapy

Savient’s Gout Drug Gets Its J-Code

BioReference Laboratories, Inc. Announces Contract with Corizon, Inc. to Provide Correctional Healthcare Laboratory Services

January 11
Dosing Begins for GOG US Cervical Cancer Study Evaluating ADXS-HPV

Cyclacel Provides Corporate Update at OneMedForum Conference

January 10
GE Healthcare Presents at JP Morgan Healthcare Conference on Role of Molecular and Companion Diagnostics in Personalized Medicine

January 9
Pacira Pharmaceuticals, Inc. Provides Update on Commercial Launch and Product Availability Timing for EXPAREL®

Kyorin and BioLeap Enter Research Collaboration

Senesco Announces $2.0 Million Equity Financing

Merck to Present at the 30th Annual J.P. Morgan Healthcare Conference

Unigene Provides 2012 Business Outlook

Photocure ASA – Photocure Strengthens the Management Team

LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes

Celgene Corporation Announces 2012 Financial Outlook and Reviews 2011 Achievements

Amicus Therapeutics Provides Full-Year 2012 Strategic Outlook and Financial Guidance

January 7
Bristol-Myers Squibb to Acquire Inhibitex

January 6
Advaxis to Present at 5th Annual OneMedForum San Francisco 2012

Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results

Amicus Therapeutics Announces Positive Preliminary Results from Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease

January 5
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2011 on January 26

January 4
Merck to Present at Goldman Sachs 2012 Healthcare Event

Regulatory Harmonization Institute: First Not-For-Profit Organization Dedicated to Global Harmonization of Drug and Medical Device Regulatory Requirements

CircuLite Awarded Grant from Cardiovascular Medical Research and Education Fund to Develop Right-Heart Circulatory Support System for Patients with Pulmonary Arterial Hypertension (PAH)

AAIPharma Services Acquires Celsis Analytical Services

Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference

Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference

December 30
CorMedix Provides Year End 2011 Update

Advaxis Receives Additional Financing

Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9

December 29
Bristol-Myers Squibb to Present at Goldman Sachs Healthcare CEOs Unscripted Conference

December 28
Immunomedics and UCB Announce Restructuring of Epratuzumab License Agreement

Celgene Corporation to Present at Two Upcoming Investor Conferences

December 23
Lexicon Announces Completion of Rights Offering to Stockholders

December 22
PTC Therapeutics’ Antibacterial Program Receives $5 Million Award from the Wellcome Trust

Bristol-Myers Squibb and the Gladstone Institutes Enter Three-Year Discovery Partnership in Alzheimer’s Disease

Celgene Corporation Announces the Appointment of Richard Bagger as Senior Vice President, Corporate Affairs and Strategic Market Access

BRISK-PS Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Completed

Amicus Therapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference

The Medicines Company to Participate in the 30th Annual J.P. Morgan Healthcare Conference 2012

December 21
Celldex Completes Accrual of CDX-011 Phase 2b “EMERGE” Study in Advanced Breast Cancer

Merck and the ADAP Crisis Task Force Announce New Agreement to Improve Access and Care for People with HIV

December 20
Bard Acquires Lutonix, Inc.

Sandford D. Smith Appointed to Aegerion Pharmaceuticals’ Board of Directors

Antares Pharma Enters Licensing Agreement with Pfizer Consumer Healthcare

December 19
Unigene’s 2011 Year in Review – Key Elements in Place to Address Debt in 2012

VaxInnate Licenses Recombinant Flu Vaccines to CJ CheilJedang Corporation of South Korea

Amicus Therapeutics Completes Enrollment of 67 Patients in Phase 3 Study of Migalastat HCl for Fabry Disease

December 16
Advaxis Reports Preliminary Data from ADXS-HPV Phase 2 Trial in Patients with Recurrent/Refractory Cervical Cancer at AACR India

Pharmasset Announces Intent to Amend QUANTUM Trial

December 15
NuGEN® Technologies Sample Preparation Solutions Selected by Rutgers University Cell and DNA Repository for Large Scale Alcoholism Study

Soligenix Initiates Next Generation Anthrax Vaccine Development Program under Agreement with Harvard University

California Biotech Moves U.S. Operations to Bridgewater

EKR Therapeutics Names Two Independent Directors and Reaffirms Board of Directors to Lead Company Growth in the Critical Care Sector

The Cough Company Is Now Alitair Pharmaceuticals, Inc.

Merck Announces Initiation of Clinical Development Collaboration with Roche to Evaluate Investigational Combination Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Infection

December 14
Meta-analysis of Five Clinical Trials including Columbia Laboratories’ PREGNANT Study Published in American Journal of Obstetrics and Gynecology

Premiere Cooperative Group in Adult Lymphoma Research (GELA) Chooses REVLIMID® for Study in Second Most Common Lymphoma Subtype

Immunomedics Awarded New Patent for Improved Cell Lines For Protein Therapeutic Manufacturing

Santa Serenades SAFE-BioPharma in Unique Musical Greeting

December 13
Immunomedics Announces Results from Two Clinical Trials at Hematology Conference

Aestus Therapeutics Reports Positive Results in Phase II Neuropathic Pain Trial for Treatment of Post-Herpetic Neuralgia

Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound

Final Phase II Data Evaluating REVLIMID® and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase III Study Evaluating REVLIMID® in Patients with High-Risk Smoldering Multiple Myeloma Presented at ASH

REVLIMID® Evaluated in Combination with Rituximab as a Potential Treatment for Patients with Treatment-Naive Chronic Lymphocytic Leukemia

December 12
Celldex Therapeutics Presents Novel Preclinical Data on CDX-1127 at the American Society of Hematology Meeting in San Diego

Soligenix Announces Publication of Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD

Immunomedics Reports Subcutaneous Injections of Low-Dose Veltuzumab Produced High Rates of Response in Relapsed Immune Thrombocytopenia

Immunomedics Develops Novel Antibody-Based Therapeutics for Mantle Cell and Other Lymphomas

Onconova Therapeutics Selects Acurian’s Clinical Trial Liaison (CTL) Service for the ONTIME Trial

Phase III Study with REVLIMID® Continuous Therapy Demonstrates Statistically Significant Improvement in Progression-Free Survival for Patients Newly Diagnosed with Multiple Myeloma

Final Data from Phase II Multi-Center Study Evaluating Combination of VIDAZA® and REVLIMID® in Higher-Risk MDS Patients Presented at ASH

Phase II Study of ISTODAX® in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL): A Sub-Analysis of Patients with Most Common Subtypes of PTCL Presented at ASH

Phase II Study Evaluates Clinical Benefit of Pomalidomide in Heavily Pre-Treated Patients with Multiple Myeloma

Antares Pharma to Present at the Oppenheimer 22nd Annual Healthcare Conference

Merck Announces Results of ZOLINZA® (vorinostat) Phase III and IIb Trials for Investigational Use for Multiple Myeloma at American Society of Hematology Annual Meeting

Updated Results from Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients with AML

December 11
Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic Lymphocytic Leukemia

Results from a Comparative Analysis Show REVLIMID® Demonstrates Statistically Significant Reduction in Risk of Death and No Evidence of Increased Risk of Progression to AML in Patients with Deletion 5q MDS Compared with Best Supportive Care

December 10
Onconova to Present Data Demonstrating Survival Benefit in MDS Patients Treated with Rigosertib and Phase I Data for Oral Rigosertib at the American Society of Hematology Annual Meeting

Phase I Study Evaluating Oral Azacitidine as Potential Treatment for Patients with Acute Myeloid Leukemia Presented at the American Society of Hematology Meeting

December 9
Ezose Sciences in New Agreement with Merck to Advance Glycan Biomarker Discovery in Diabetes

Immunomedics Creates Targeted Therapeutics for Solid Cancers

December 8
The Avoca Group Announces Consortium on Quality Management and Oversight Sponsored by Eli Lilly and Pfizer

Bio-Reference Laboratories, Inc. Announces Record Revenues, Earnings and Cash Flow

Cegedim Relationship Management’s Senior DEA Compliance Consultant Receives Attorney General’s Award for Management and Coordination of First Nationwide Prescription Drug Take-Back Campaign

Antares’ Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder

Enzon Presents Data from Phase II PEG-SN38 (EZN-2208) Study in Patients with Metastatic Breast Cancer

New Data Show Investigational Compound Dapagliflozin When Added to Glimepiride Maintained Reductions in Blood Sugar Levels in Adults with Type 2 Diabetes Over 48 Weeks of Treatment

December 7
BioReference Laboratories, Inc. to Speak at the Oppenheimer 22nd Annual Healthcare Conference

Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011

Cyclacel Provides Update on Clinical Progress with Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients

Immunomedics Announces Outcome of 2011 Annual Meeting of Stockholders

Shionogi & Co., Ltd. and Shionogi Inc. Announce a Favorable Decision in FORTAMET® Preliminary Injunction Proceedings

CRI Worldwide and Lifetree Clinical Research Announce New Company Name—CRI Lifetree

Cegedim Relationship Management Launches Innovative Regulatory Compliance Solution for Risk Evaluation and Mitigation Strategies (REMS)

BioReference Laboratories, Inc. Announces Earnings Date for Fourth Quarter and Year End for Fiscal Year 2011

Aegerion Expands Global Commercial Team

December 6
Merck Establishes New MSD R&D Asia Headquarters

Ezose Sciences Aligns to Add Diagnostics Capabilities to Its Core Biomarker Discovery Programs

Ranbaxy Launches Authorized Generic Version of Caduet® In the U.S.

Immunomedics to Present at Oppenheimer 22nd Annual Healthcare Conference

Senesco to Present at the 53rd Annual Meeting of the American Society of Hematology on SNS01-T

Aegerion Pharmaceuticals Adds to Management Team Anne Marie Cook as SVP, General Counsel, and Mary Weger as SVP, Human Resources

Bristol-Myers Squibb Announces Dividend Increase

December 5
Unigene Regains Exclusive Worldwide Rights of Oral PTH from GSK

The Medicines Company Invests Equity Stake in GeNO, LLC, Nitric Oxide Delivery and Technology Company

Merck for Mothers and PATH Collaborate to Identify Innovations that Save Mothers’ Lives

December 2
Edge Therapeutics Receives Success Award from New Jersey Small Business Development Centers